Zantac Cancer Contamination Could Occur In the Body
Scientists and government regulators are concerned that Zantac could have become carcinogenic after it was ingested
Monday, August 31, 2020 - Sanofi, the maker of Zantac, claims that online testing pharmacy valisure may be responsible for causing the NDMA spike that has created a public health crisis. Zantac is being accused of causing cancer of the stomach, bladder, prostate, and many other forms and could have created a public health crisis that is just beginning to unfold. Since tens of millions of people have used Zantac regularly over the years the US government has launched its investigation into the causes of increases in the carcinogen. Sanofi is being sued by thousands of former Zantac users for failing to warn them of what they knew or should have known about Zantac causing cancer. Cancer's latency period of over a decade has allowed the drug to escape health testing scrutiny until now.
The US Food and Drug Administration (FDA) is trying to identify the reason why ranitidine sold under the brand name of Zantac among others has tested positive for elevated levels of NDMA. Reuters reported last July, "... FDA spokesman Jeremy Kahn said the regulator is now "working to understand what happens to NDMA levels in the body after ranitidine has been exposed to acid in the stomach." David Light, CEO of online testing pharmacy Valisure is concerned that NDMA could accelerate when it is combined with nitrites in spicey, processed meats from hot dogs to sausages and more, ironically the same foods that cause one in the past to reach for a Zantac. "This is one of the main red flags we've raised the whole time - not just contamination but the fact that this is happening in the human body." Mr. Light told Reuters. If you or a loved one has developed cancer and has used Zantac regularly for years you may want to speak with a Zantac Cancer Lawyer for a free, no-obligation analysis of your individual situation.
Also, the DOJ is looking into what Sanofi may have known and withheld about Zantac NDMA cancer. According to NY Legal Examiner, the Department of Justice is concerned that Sanofi executive may have lied to consumers for decades. "According to Reuters, both companies (Sanofi and subsidiary) received civil investigative demands from the Justice Department last month seeking information related to Zantac. The U.S. Food and Drug Administration (FDA) requested the recall of all Zantac and generic ranitidine medications on April 1, 2020, after independent tests indicated that NDMA levels could increase over time and when stored at higher than room temperatures." "The DOJ is looking into claims that the pharmaceutical companies violated the False Claims Act by failing to disclose to the public or to healthcare providers that Zantac and generic ranitidine medications could contain NDMA," according to NYLE.
It has been speculated that NDMA can increase to thousands of times the FDA-acceptable level of 96ng per tablet when the ranitidine is stored at high temperatures or by incompetent overseas manufacturers in China and elsewhere.
More Recent Heartburn MedicineLawsuit News:
- Zantac Cancer Trials Are In Discovery To Begin In October 2022 | 7/19/2022
- Zantac Cancer Lawsuits Could Hinge On The Validity of Ranitidine Testing Methods | 7/11/2022
- Zantac Cancer Bellwether Trials In California Could Set The Stage For A Global Settlement Offer | 7/5/2022
- The FDA Recommended Protein Pump Inhibitor Drugs Like Prilosec And Nexium That May Damage Health More Than Zantac | 6/23/2022
- Truck Drivers, Firefighters, and Police Officers May Have Taken More Zantac Than People In Other Occupations | 6/20/2022
- Scientists Are Expected To Confirm That Ranidine Causes Gastrointestinal Cancer With Slam Dunk Testimony | 6/9/2022
- Scientific Hearings Will Start This September To Interview Zantac Cancer Expert Witnesses | 5/19/2022
- A Whistleblower Scientist Working For A Chinese Company Thinks NDMA Contamination Started In China | 5/12/2022
- Valisure's String Of Stunning Success Casts Doubt On The FDAs Ability To Police The Health Care Market | 5/2/2022
- Zantac Testing Accusations Heat Up With FDA Investigation Of Online Prescription Drug Testing Lab | 4/25/2022
- Study Finds Ranitidine Degrades Into 10,000 Nanograms of NDMA When Introduced To Simulated Stomach Conditions | 4/6/2022
- Potential Zantac Expert Witnesses Are Being Questioned By Zantac Defense Attorneys | 3/31/2022
- The FDA Requires That Drug Companies Regularly Test Ranitidine And Other Drug For NDMA | 3/24/2022
- Update: Where The Zantac Cancer Multidistrict Litigation (MDL) Stands Today | 3/12/2022
- Zantac Cancer Plaintiffs Look To The First Trial In October In Alameda California | 3/11/2022
- Zantac Cancer Plaintiffs Have Until June 30 To Finalize Their Claim | 3/7/2022
- Zantac Bellwether Trials May Focus On Ranitidine Testing Methods That Could Cause NDMA To Accelerate | 3/1/2022
- Valisure LLC's Motivations And Ranitidine Testing Methods May Not Be Scrutinized Before Trial | 2/24/2022
- Zantac Lawsuits May Go To Trial In California In October Of This Year | 2/18/2022
- Sanofi's History Of Reprehensible Corporate Behavior May Bolster Zantac Cancer Lawsuits | 2/10/2022
Lawyers for Zantac Heartburn Medicine Lawsuits
OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.